Arvinas, Inc. (ARVN) stock
ARVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/30
$6.82+0.05 (+0.74%)
Close on Nov 17, 2026Market cap $445.93MP/E 42.6Yield –
Arvinas ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Arvinas's ebitda for the twelve months ending Jun 30, 2026 was -$15.20M. For fiscal 2025 it was -$115.50M. The highest annual figure on record is -$24.41M in fiscal 2017.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$115.50M | – |
| FY2024 | Dec 31, 2024 | -$245.60M | – |
| FY2023 | Dec 31, 2023 | -$396.70M | – |
| FY2022 | Dec 31, 2022 | -$256.90M | – |
| FY2021 | Dec 31, 2021 | -$183.60M | – |
| FY2020 | Dec 31, 2020 | -$117.60M | – |
| FY2019 | Dec 31, 2019 | -$49.90M | – |
| FY2018 | Dec 31, 2018 | -$43.10M | – |
| FY2017 | Dec 31, 2017 | -$24.41M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $164.80M | – |
| Q1 FY2026 | Mar 31, 2026 | -$63.10M | -187.5% |
| Q4 FY2025 | Dec 31, 2025 | -$73.90M | – |
| Q3 FY2025 | Sep 30, 2025 | -$43.00M | – |
| Q2 FY2025 | Jun 30, 2025 | -$70.70M | – |
| Q1 FY2025 | Mar 31, 2025 | $72.10M | – |
| Q4 FY2024 | Dec 31, 2024 | -$57.10M | – |
| Q3 FY2024 | Sep 30, 2024 | -$59.20M | – |
| Q2 FY2024 | Jun 30, 2024 | -$47.30M | – |
| Q1 FY2024 | Mar 31, 2024 | -$82.10M | – |
| Q4 FY2023 | Dec 31, 2023 | -$164.10M | – |
| Q3 FY2023 | Sep 30, 2023 | -$72.70M | – |
| Q2 FY2023 | Jun 30, 2023 | -$73.40M | – |
| Q1 FY2023 | Mar 31, 2023 | -$86.50M | – |
| Q4 FY2022 | Dec 31, 2022 | -$73.90M | – |
| Q3 FY2022 | Sep 30, 2022 | -$62.70M | – |
| Q2 FY2022 | Jun 30, 2022 | -$64.30M | – |
| Q1 FY2022 | Mar 31, 2022 | -$56.20M | – |
| Q4 FY2021 | Dec 31, 2021 | -$46.20M | – |
| Q3 FY2021 | Sep 30, 2021 | -$46.10M | – |
| Q2 FY2021 | Jun 30, 2021 | -$50.70M | – |
| Q1 FY2021 | Mar 31, 2021 | -$40.60M | – |
| Q4 FY2020 | Dec 31, 2020 | -$38.07M | – |
| Q3 FY2020 | Sep 30, 2020 | -$30.89M | -617.1% |
| Q2 FY2020 | Jun 30, 2020 | -$25.85M | – |
| Q1 FY2020 | Mar 31, 2020 | -$22.79M | – |
| Q4 FY2019 | Dec 31, 2019 | -$22.21M | – |
| Q3 FY2019 | Sep 30, 2019 | $5.97M | – |
| Q2 FY2019 | Jun 30, 2019 | -$18.11M | – |
| Q1 FY2019 | Mar 31, 2019 | -$15.57M | – |
| Q4 FY2018 | Dec 31, 2018 | -$16.72M | – |
| Q3 FY2018 | Sep 30, 2018 | -$13.87M | – |
| Q2 FY2018 | Jun 30, 2018 | -$8.35M | – |
| Q1 FY2018 | Mar 31, 2018 | -$4.16M | – |
| Q4 FY2017 | Dec 31, 2017 | -$5.21M | – |
See a number that looks wrong?